Loading...

BioMarin Pharmaceutical

DB:BM8
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BM8
DB
$15B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
BM8 Share Price and Events
7 Day Returns
-6.6%
DB:BM8
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
13.3%
DB:BM8
-10.6%
DE Biotechs
-6.2%
DE Market
BM8 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioMarin Pharmaceutical (BM8) -6.6% -4.7% -7.4% 13.3% -5.1% 82.7%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • BM8 outperformed the Biotechs industry which returned -10.6% over the past year.
  • BM8 outperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
BM8
Industry
5yr Volatility vs Market

Value

 Is BioMarin Pharmaceutical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioMarin Pharmaceutical to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioMarin Pharmaceutical.

DB:BM8 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 26 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:BM8
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.449 (1 + (1- 21%) (5.56%))
1.343
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.34
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.343 * 5.96%)
8.24%

Discounted Cash Flow Calculation for DB:BM8 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioMarin Pharmaceutical is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:BM8 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.24%)
2019 -28.00 Analyst x3 -25.87
2020 72.50 Analyst x2 61.89
2021 14.00 Analyst x1 11.04
2022 270.00 Analyst x1 196.74
2023 676.00 Analyst x1 455.10
2024 1,055.55 Est @ 56.15% 656.55
2025 1,471.13 Est @ 39.37% 845.42
2026 1,877.57 Est @ 27.63% 996.89
2027 2,241.97 Est @ 19.41% 1,099.80
2028 2,548.08 Est @ 13.65% 1,154.86
Present value of next 10 years cash flows $5,452.42
DB:BM8 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $2,548.08 × (1 + 0.23%) ÷ (8.24% – 0.23%)
$31,895.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $31,895.11 ÷ (1 + 8.24%)10
$14,455.74
DB:BM8 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $5,452.42 + $14,455.74
$19,908.16
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $19,908.16 / 178.37
$111.61
DB:BM8 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:BM8 represents 0.90145x of NasdaqGS:BMRN
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90145x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 111.61 x 0.90145
€100.61
Value per share (EUR) From above. €100.61
Current discount Discount to share price of €75.46
= -1 x (€75.46 - €100.61) / €100.61
25%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price BioMarin Pharmaceutical is available for.
Intrinsic value
25%
Share price is €75.46 vs Future cash flow value of €100.61
Current Discount Checks
For BioMarin Pharmaceutical to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • BioMarin Pharmaceutical's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • BioMarin Pharmaceutical's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioMarin Pharmaceutical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioMarin Pharmaceutical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:BM8 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.44
NasdaqGS:BMRN Share Price ** NasdaqGS (2019-04-23) in USD $83.71
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioMarin Pharmaceutical.

DB:BM8 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:BMRN Share Price ÷ EPS (both in USD)

= 83.71 ÷ -0.44

-191.96x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioMarin Pharmaceutical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • BioMarin Pharmaceutical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioMarin Pharmaceutical's expected growth come at a high price?
Raw Data
DB:BM8 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -191.96x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 26 Analysts
60.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioMarin Pharmaceutical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioMarin Pharmaceutical's assets?
Raw Data
DB:BM8 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $16.65
NasdaqGS:BMRN Share Price * NasdaqGS (2019-04-23) in USD $83.71
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:BM8 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:BMRN Share Price ÷ Book Value per Share (both in USD)

= 83.71 ÷ 16.65

5.03x

* Primary Listing of BioMarin Pharmaceutical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioMarin Pharmaceutical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioMarin Pharmaceutical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioMarin Pharmaceutical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioMarin Pharmaceutical expected to perform in the next 1 to 3 years based on estimates from 26 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
60.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioMarin Pharmaceutical expected to grow at an attractive rate?
  • BioMarin Pharmaceutical's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioMarin Pharmaceutical's earnings growth is expected to exceed the Germany market average.
  • BioMarin Pharmaceutical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:BM8 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:BM8 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 26 Analysts 60.3%
DB:BM8 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 26 Analysts 15.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:BM8 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 26 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:BM8 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 3,348 1,202 909 11
2022-12-31 2,700 809 499 14
2021-12-31 2,240 538 218 18
2020-12-31 1,944 338 46 25
2019-12-31 1,693 218 -74 26
DB:BM8 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1,491 20 -77
2018-09-30 1,496 -15 -125
2018-06-30 1,439 -23 -125
2018-03-31 1,383 29 -145
2017-12-31 1,314 -9 -117
2017-09-30 1,255 -24 -156
2017-06-30 1,201 -72 -181
2017-03-31 1,184 -137 -563
2016-12-31 1,117 -228 -630
2016-09-30 1,045 -293 -471
2016-06-30 974 -286 -524
2016-03-31 924 -253 -187

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioMarin Pharmaceutical's earnings are expected to grow significantly at over 20% yearly.
  • BioMarin Pharmaceutical's revenue is expected to grow by 15.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:BM8 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 26 Analyst Estimates (S&P Global) See Below

All data from BioMarin Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BM8 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 3.99 5.16 2.10 8.00
2022-12-31 2.49 3.97 1.30 11.00
2021-12-31 1.16 2.61 -0.27 15.00
2020-12-31 0.26 1.31 -0.69 22.00
2019-12-31 -0.42 -0.15 -0.61 22.00
DB:BM8 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.44
2018-09-30 -0.71
2018-06-30 -0.71
2018-03-31 -0.83
2017-12-31 -0.67
2017-09-30 -0.90
2017-06-30 -1.06
2017-03-31 -3.34
2016-12-31 -3.80
2016-09-30 -2.88
2016-06-30 -3.25
2016-03-31 -1.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • BioMarin Pharmaceutical is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess BioMarin Pharmaceutical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioMarin Pharmaceutical has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioMarin Pharmaceutical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioMarin Pharmaceutical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioMarin Pharmaceutical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare BioMarin Pharmaceutical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioMarin Pharmaceutical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
BioMarin Pharmaceutical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioMarin Pharmaceutical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:BM8 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1,491.21 -77.21 604.35
2018-09-30 1,496.30 -124.95 600.46
2018-06-30 1,438.75 -124.86 582.43
2018-03-31 1,383.35 -144.90 572.65
2017-12-31 1,313.65 -117.04 554.34
2017-09-30 1,255.43 -156.37 537.01
2017-06-30 1,201.18 -181.27 525.24
2017-03-31 1,183.86 -563.45 491.31
2016-12-31 1,116.85 -630.21 476.59
2016-09-30 1,044.70 -470.87 440.54
2016-06-30 973.71 -524.37 415.83
2016-03-31 923.71 -187.35 407.77
2015-12-31 889.90 -171.80 402.27
2015-09-30 892.03 -310.21 385.43
2015-06-30 859.00 -211.84 365.62
2015-03-31 800.65 -163.36 332.09
2014-12-31 749.28 -133.97 299.46
2014-09-30 666.09 -126.16 273.90
2014-06-30 627.09 -186.63 261.51
2014-03-31 572.11 -174.66 244.18
2013-12-31 548.49 -176.35 235.36
2013-09-30 533.55 -167.38 218.60
2013-06-30 524.79 -119.71 203.09
2013-03-31 512.00 -130.19 203.98
2012-12-31 500.72 -114.35 198.17
2012-09-30 476.63 -88.07 191.58
2012-06-30 461.94 -100.37 190.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioMarin Pharmaceutical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioMarin Pharmaceutical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioMarin Pharmaceutical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioMarin Pharmaceutical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioMarin Pharmaceutical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioMarin Pharmaceutical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioMarin Pharmaceutical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioMarin Pharmaceutical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioMarin Pharmaceutical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioMarin Pharmaceutical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioMarin Pharmaceutical Company Filings, last reported 3 months ago.

DB:BM8 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,967.94 830.42 1,084.31
2018-09-30 2,914.95 1,200.35 1,443.38
2018-06-30 2,885.10 1,191.62 1,363.07
2018-03-31 2,807.00 1,183.00 1,382.80
2017-12-31 2,808.66 1,174.47 1,395.97
2017-09-30 2,813.56 1,166.04 1,257.10
2017-06-30 2,795.58 676.21 727.78
2017-03-31 2,769.09 690.93 678.06
2016-12-31 2,766.28 683.24 789.68
2016-09-30 2,645.81 675.64 1,034.85
2016-06-30 1,917.58 670.11 503.29
2016-03-31 2,290.24 668.01 456.85
2015-12-31 2,400.85 662.29 592.62
2015-09-30 2,292.64 667.79 618.33
2015-06-30 2,356.96 661.49 681.55
2015-03-31 2,425.46 655.49 1,008.69
2014-12-31 1,527.89 642.90 945.19
2014-09-30 1,508.44 656.88 666.37
2014-06-30 1,461.97 650.87 836.62
2014-03-31 1,460.12 661.42 887.48
2013-12-31 1,341.04 655.57 784.72
2013-09-30 1,276.49 78.31 379.65
2013-06-30 1,258.26 109.82 400.56
2013-03-31 1,250.15 109.85 401.88
2012-12-31 1,015.76 348.22 447.81
2012-09-30 1,015.19 348.30 426.46
2012-06-30 1,000.43 348.31 402.59
  • BioMarin Pharmaceutical's level of debt (28%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (48.8% vs 28% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioMarin Pharmaceutical has sufficient cash runway for more than 3 years based on current free cash flow.
  • BioMarin Pharmaceutical has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -72.5% each year.
X
Financial health checks
We assess BioMarin Pharmaceutical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioMarin Pharmaceutical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioMarin Pharmaceutical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioMarin Pharmaceutical dividends. Estimated to be 0% next year.
If you bought €2,000 of BioMarin Pharmaceutical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioMarin Pharmaceutical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioMarin Pharmaceutical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:BM8 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 26 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:BM8 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 4.00
2019-12-31 0.00 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioMarin Pharmaceutical has not reported any payouts.
  • Unable to verify if BioMarin Pharmaceutical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioMarin Pharmaceutical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioMarin Pharmaceutical has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of BioMarin Pharmaceutical's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess BioMarin Pharmaceutical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioMarin Pharmaceutical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioMarin Pharmaceutical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioMarin Pharmaceutical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jean-Jacques Bienaimé
COMPENSATION $15,916,985
AGE 65
TENURE AS CEO 13.9 years
CEO Bio

Mr. Jean-Jacques Bienaime, MBA, has been the Chief Executive Officer of Biomarin Pharmaceutical Inc. since June 2005. He served as Director at Vital Therapies, Inc. since September 2013 to October 10, 2018. Mr. Bienaime served as the Chief Executive Officer and President of Danisco US Inc. (formerly, Genencor) from November 2002 to April 2005. He has over 25 years of experience in the biotechnology and pharmaceutical industries. Before Genencor, he served as the President since June 1998, Chief Executive Officer since February 1999 and Chief Operating Officer from June 1998 to February 1999 at SangStat Medical Corporation. From 1992 to 1998, Mr. Bienaime held several senior management positions at Rhone-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), including Senior Vice President of Corporate Marketing and Business Development and Vice President and General Manager of the advanced therapeutic and oncology division. He worked at Genentech, Inc., where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. He served as the Director of Marketing, Cardiopulmonary Products at Genentech Inc. Mr. Bienaime has been the Chairman of the Board at Biomarin Pharmaceutical Inc. since June 9, 2015. He served as Chairman of Danisco US Inc. (formerly, Genencor) from April 2003 to May 2005, SangStat Medical Corporation from 1998 to November 2002 and NeurogesX Inc. from May 29, 2007 to April 2011. He has been a Director of Biomarin Pharmaceutical Inc. since May 2005, Incyte Corporation since January 20, 2015. He serves as a Member of Advisory Board at BB Biotech Ventures G.P. and BB Biotech Ventures II. Mr. Bienaimé served as a Director of InterMune, Inc. since March 27, 2012 until September 29, 2014. He served as a Director of SangStat Medical Corporation since March 1999. He served as an Independent Director of Portola Pharmaceuticals, Inc. from September 23, 2010 to June 30, 2014. He served as Lead Director and Director of Saegis Pharmaceuticals Inc. He served as a Director of Danisco US Inc. from November 2002 to April 2005. He served as a Director of Aerogen Inc. since 1999 and served as its Lead Director since June 30, 2005. He served as Director of StemCells Inc. and Ensemble Therapeutics Corporation. Mr. Bienaimé served as a Lead Director of NeurogesX Inc. from April 2011 to June 7, 2012 and its Director from February 2004 to June 7, 2012. In June 2004, Mr. Bienaimé is a director of the Biotech Industry Organization and the Pharmaceutical Research and Manufacturers of America® (PhRMA). He serves as a Director of Fox Chase Cancer Center in Philadelphia. Mr. Bienaimé received an MBA degree from the Wharton School at the University of Pennsylvania and a B.S. Degree in Economics from Ecole Superieure de Commerce de Paris in France.

CEO Compensation
  • Jean-Jacques's compensation has been consistent with company performance over the past year.
  • Jean-Jacques's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioMarin Pharmaceutical management team in years:

8.1
Average Tenure
59
Average Age
  • The average tenure for the BioMarin Pharmaceutical management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jean-Jacques Bienaimé

TITLE
Chairman & CEO
COMPENSATION
$16M
AGE
65
TENURE
13.9 yrs

Dan Spiegelman

TITLE
Executive VP & CFO
COMPENSATION
$5M
AGE
59

Robert Baffi

TITLE
Executive Vice President of Technical Operations
COMPENSATION
$4M
AGE
63

Jeff Ajer

TITLE
Executive VP & Chief Commercial Officer
COMPENSATION
$5M
AGE
56
TENURE
6.5 yrs

Hank Fuchs

TITLE
President of Worldwide Research & Development
COMPENSATION
$7M
AGE
60
TENURE
2.5 yrs

Brian Mueller

TITLE
Senior VP of Finance & Chief Accounting Officer
AGE
44
TENURE
8.1 yrs

Lon Cardon

TITLE
Senior VP & Chief Scientific Officer

Traci McCarty

TITLE
Vice President of Investor Relations

George Davis

TITLE
Executive VP
COMPENSATION
$3M
AGE
47
TENURE
15.3 yrs

Philip Scalzo

TITLE
Senior VP & Chief Compliance Officer
Board of Directors Tenure

Average tenure and age of the BioMarin Pharmaceutical board of directors in years:

11.8
Average Tenure
65.5
Average Age
  • The average tenure for the BioMarin Pharmaceutical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jean-Jacques Bienaimé

TITLE
Chairman & CEO
COMPENSATION
$16M
AGE
65
TENURE
3.8 yrs

Elaine Heron

TITLE
Independent Director
COMPENSATION
$466K
AGE
70
TENURE
16.8 yrs

Mike Grey

TITLE
Independent Director
COMPENSATION
$457K
AGE
65
TENURE
13.3 yrs

Alan Lewis

TITLE
Independent Director & Member of Sciencetific Advisory Board
COMPENSATION
$456K
AGE
72
TENURE
13.8 yrs

Bob Hombach

TITLE
Director
COMPENSATION
$339K
AGE
52
TENURE
1.6 yrs

Randy Meier

TITLE
Lead Independent Director
COMPENSATION
$519K
AGE
58
TENURE
3.8 yrs

V. Lawlis

TITLE
Independent Director
COMPENSATION
$449K
AGE
66
TENURE
11.8 yrs

Joseph Loscalzo

TITLE
Member of Sciencetific Advisory Board
AGE
67

David Rimoin

TITLE
Member of Sciencetific Advisory Board

Jeffrey Borer

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Sep 18 Sell George Davis Individual 14. Sep 18 14. Sep 18 -2,216 €85.28 €-188,981
17. Sep 18 Sell George Davis Individual 13. Sep 18 13. Sep 18 -12,000 €85.26 €-1,023,141
07. Sep 18 Sell Elaine Heron Individual 05. Sep 18 05. Sep 18 -1,000 €83.47 €-83,471
28. Aug 18 Sell Henry Fuchs Individual 24. Aug 18 27. Aug 18 -25,000 €85.68 €-2,131,290
22. Aug 18 Sell Alan Lewis Individual 21. Aug 18 21. Aug 18 -4,200 €86.84 €-364,709
X
Management checks
We assess BioMarin Pharmaceutical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioMarin Pharmaceutical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.

Details
Name: BioMarin Pharmaceutical Inc.
BM8
Exchange: DB
Founded: 1996
$13,324,903,645
178,372,202
Website: http://www.biomarin.com
Address: BioMarin Pharmaceutical Inc.
770 Lindaro Street,
San Rafael,
California, 94901,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS BMRN Common Stock Nasdaq Global Select US USD 23. Jul 1999
DB BM8 Common Stock Deutsche Boerse AG DE EUR 23. Jul 1999
LSE 0HNC Common Stock London Stock Exchange GB USD 23. Jul 1999
WBAG BMRN Common Stock Wiener Boerse AG AT EUR 23. Jul 1999
Number of employees
Current staff
Staff numbers
2,849
BioMarin Pharmaceutical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 20:35
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/22
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.